- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Results
4
Companies which are potentially undervalued and in an acceptable financial position.
4 companies
Roche Holding
Market Cap: CHF 263.0b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 326.10
7D
1.1%
1Y
24.0%
Tecan Group
Market Cap: CHF 1.9b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 149.20
7D
-3.7%
1Y
-9.1%
Bachem Holding
Market Cap: CHF 4.9b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 66.60
7D
-2.7%
1Y
23.0%
Basilea Pharmaceutica
Market Cap: CHF 617.9m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 49.80
7D
1.6%
1Y
-3.3%